Some cannabinoids activate the different isoforms of PPARs (α, β and γ), as shown through
the use of reporter gene assays, binding studies, selective antagonists and knockout …

The endocannabinoid system consists of G protein-coupled cannabinoid CB 1 and CB 2
receptors, of endogenous compounds known as endocannabinoids that can target these …

Cannabinoids are a group of compounds that mediate their effects through cannabinoid
receptors. The discovery of Δ9-tetrahydrocannabinol (THC) as the major psychoactive …

Arachidonoylglycerol (2-AG) is a signaling lipid in the central nervous system that is a key
regulator of neurotransmitter release. 2-AG is an endocannabinoid that activates the …

CB1 and CB2 receptors are activated by a plethora of cannabinoid compounds, be they
endogenously‐produced, plant‐derived or synthetic. These receptors are expressed by …

The endocannabinoid system was revealed following the understanding of the mechanism
of action of marijuana's major psychotropic principle, Δ 9-tetrahydrocannabinol, and …

Cannabinoids act at two classical cannabinoid receptors (CB1 and CB2), a 7TM orphan
receptor and the transmitter‐gated channel transient receptor potential vanilloid type‐1 …

Arachidonoyl-glycerol (2-AG) and arachidonyl-ethanolamide (AEA) are endocannabinoids
that have been implicated in many physiologic disorders, including obesity, metabolic …

It is widely accepted that non-endogenous compounds that target CB1 and/or CB2 receptors
possess therapeutic potential for the clinical management of an ever growing number of …

Cannabinoids have numerous physiological effects. In the years since the molecular
identification of the G protein‐coupled receptors CB1 and CB2, the ion channel TRPV1, and …